跳至主要内容
临床试验/NCT03517384
NCT03517384已完成不适用

Feasibility Pilot Study of Internet-based CBT for Body Dysmorphic Disorder With Global Recruitment

Karolinska Institutet2 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2016年4月20日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
32
试验地点
2
主要终点
Symptom Change using the Clinician-rated, Body Dysmporhic Disorder Modification of Yale-Brown Obsessive Compulsive Scale (BDD-YBOCS)

研究概览

简要总结

The aim of the study is to study an english-language version of BDD-NET (Enander, et al., 2014; Enander, et al., 2016), an internet-based treatment for Body Dysmorphic Disorder, on a globally recruited sample. This is an uncontrolled pilot study where a within-subjects repeated measures design was used to assess the feasibility of conducting all aspects of the study remotely, including recruitment, assessment, and treatment delivery.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Current outpatient status (not currently admitted for inpatient care)
  • Patient is fluent in English
  • Patient has regular access to a computer with an Internet connection
  • Patient has adequate skills to use the Internet effectively.
  • Patient provides informed consent (both verbal, and click yes to consent on secure web page)
  • Patient is 18 years of age or older (able to provide government issued photo ID)
  • Patient has primary diagnosis of DSM-5 Body Dysmorphic Disorder, (determined using the SCID-5 module "G" which assesses diagnostic criteria on obsessive compulsive spectrum disorders)
  • score ≥ 4 on the Body Dysmorphic Disorder Questionnaire (BDDQ),
  • score ≥ 9 on the Dysmorphic Concern Questionnaire (DCQ)
  • score ≥ 20 on the Body Dysmorphic Disorder Modification of the Yale Brown Obsessive Compulsive Scale (BDD-YBOCS).

排除标准

  • Patient received Cognitive Behavior Therapy for Body Dysmporphic Disorder in the 12 months preceding treatment
  • Patient changed psychotropic medications within the 12 weeks before treatment
  • Patient receiving other ongoing psychotherapy at the time,
  • Patient did not have access to a 24 hour psychiatric emergency center
  • Patient could not provide an emergency contact person.
  • Current substance dependence (assessed with M.I.N.I. 7.0, AUDIT, DUDIT)
  • Lifetime bipolar disorder diagnosis (assessed with M.I.N.I. 7.0 and self-report)
  • Psychosis present
  • Severe depression (assessed with M.I.N.I., MADRS-S score ≥ 35)
  • Personality disorder diagnosis (self-report and video-conference diagnostic interview),
  • Lifetime history of suicide attempts (self-report) or clinically significant current suicidal ideation (≥ 5 on item 9 of MADRS-S; Columbia Suicide Severity Rating Scale (C-SSRS Lifetime Recent) - Clinical Version: Recent (past month) - Most Severe Ideation score ≥ 4).
  • Additionally, eligibility continues to be assessed on an ongoing basis after initial inclusion. The MADRS-S, Appearance Anxiety Questionnaire (AAI), and Adverse Events Questionnaire (AEQ) are administered weekly in order to ensure that the treatment study continues to be a safe and appropriate level of care for participants.

结局指标

主要结局

Symptom Change using the Clinician-rated, Body Dysmporhic Disorder Modification of Yale-Brown Obsessive Compulsive Scale (BDD-YBOCS)

时间窗: baseline, week 6, post (week 12), 3 month follow-up, 12 month follow-up

A measure of BDD symptom severity. Scores range from 0-48 with higher scores indicating greater severity.

次要结局

  • Structured Clinical Interview for Diagnostic Statistical Manual 5th edition (DSM 5) - Research Version (SCID-5-RV) module G(baseline, post (week 12), 3 month follow-up, 12 month follow-up)
  • Mini-International Neuropsychiatric Interview - version 7.0 (M.I.N.I. 7.0)(baseline, post (week 12), 3 month follow-up, 12 month follow-up)
  • Dysmorphic Concerns Questionnaire (DCQ)(screening, baseline, post (week 12), 3 month follow-up, 12 month follow-up)
  • Appearance Anxiety Inventory (AAI)(screening, baseline, weeks 1-11, post (week 12), 3 month follow-up, 12 month follow-up)
  • Brown Assessment of Beliefs Scale (BABS)(baseline, post (week 12), 3 month follow-up, 12 month follow-up)
  • Montgomery-Åsberg Depression Rating Scale, self-report (MADRS-S)(screening, baseline, weeks 1-11, post (week 12), 3 month follow-up, 12 month follow-up)
  • Skin-Picking Scale - Revised (SPS-R)(baseline, post (week 12), 3 month follow-up, 12 month follow-up)
  • Global Assessment of Functioning (GAF)(baseline, post (week 12), 3 month follow-up, 12 month follow-up)
  • Clinical Global Impressions Scale - Severity (CGI-S)(baseline, post (week 12), 3 month follow-up, 12 month follow-up)
  • Clinical Global Impressions Scale - Improvement (CGI-I)(post (week 12), 3 month follow-up, 12 month follow-up)
  • EuroQol - 5 Dimension Questionnaire (EQ-5D)(baseline, post (week 12), 3 month follow-up, 12 month follow-up)
  • Sheehan Disability Scale (SDS)(baseline, post (week 12), 3 month follow-up, 12 month follow-up)
  • Client Satisfaction Inventory (CSI)(weeks 2, 7, and 12 (post))
  • Working Alliance Inventory - Short Revised (WAI-SR)(weeks 2, 4, 6, 8, 10, and 12 (post))
  • Credibility Scale (Credibility/Expectancy Questionnaire)(baseline, weeks 2, 4, 6, 8, 10, and 12 (post))
  • Internet Cognitive Behavioral Therapy -- Exposure and Response Prevention Adherence Scale (ICBT - EX/RP Adherence Scale, modified from the Patient EX/RP Adherence Scale (PEAS))(weeks 2-11, and week 12 (post))
  • Completion of Core Treatment Modules(Post treatment (Week 12))
  • Early Termination Checklist(Post treatment (Week 12))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Christian Rück

Associate Professor

Karolinska Institutet

研究点 (2)

Loading locations...

相似试验

Feasibility Pilot Study of Internet-based Cognitive... | 临床试验